
浏览全部资源
扫码关注微信
武警重庆总队医院内分泌科,重庆 400061
丁秋,Email:893288205@qq.com,研究方向:内分泌及代谢病相关研究。
廖 涌,Email:liaoyong00133@sina.com。
收稿:2026-09-30,
录用:2026-09-30,
网络首发:2026-10-21,
移动端阅览
丁秋, 尹经霞, 董晓颖, 等. 中国高尿酸血症与痛风诊疗指南(2024)解读[J/OL]. 重庆医科大学学报, 2026,1-6.
Ding Qiu,Yin Jingxia,Dong Xiaoying,et al.Interpretation of the 2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout[J].Journal of Chongqing Medical University,
丁秋, 尹经霞, 董晓颖, 等. 中国高尿酸血症与痛风诊疗指南(2024)解读[J/OL]. 重庆医科大学学报, 2026,1-6. DOI:
Ding Qiu,Yin Jingxia,Dong Xiaoying,et al.Interpretation of the 2024 Update of Chinese Guidelines for Diagnosis and Treatment of Hyperuricemia and Gout[J].Journal of Chongqing Medical University, DOI:10.13406/j.cnki.cyxb..
近年来,随着高尿酸血症与痛风相关研究不断深入,新的循证医学证据持续涌现,我国高尿酸血症与痛风的疾病负担日益加重,患病人群呈明显年轻化趋势。中华医学会内分泌学分会整合近5年新增循证医学证据,发布《中国高尿酸血症与痛风诊疗指南(2024)》,分为一般患者和伴常见合并症的患者两个部分,围绕17个临床关键问题提出推荐意见,涵盖高尿酸血症和痛风的分型治疗与停药指征、尿酸排泄分型指导用药、抗炎镇痛策略、慢性痛风管理、生殖期患者管理及合并多系统疾病的个体化诊疗等诸多既往有争议的领域。本文就该指南相较于2019版指南的主要更新要点进行系统解读,包括降尿酸药物的选择与联合用药、痛风反复发作的抗炎镇痛、碱化尿液与饮食干预、尿酸正常的痛风的诊断、痛风发作风险评估,合并慢性肾脏病、心力衰竭/急性心肌梗死、消化道疾病、2型糖尿病和骨关节炎等合并症时的综合管理原则,以期帮助临床医师准确理解并规范应用新版指南,进行患者标准化评估与个体化施治,进一步改善疾病预后,提高患者生活质量。
In recent years,advances in research on hyperuricemia and gout have yielded a steady stream of new evidence,while the disease burden in China has grown increasingly heavy,with a marked trend toward younger age at onset. Integrating evidence accumulated over the past five years,Chinese Society of Endocrinology released the Chinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout(2024),which addresses 17 key clinical questions. This article systematically interprets its major updates compared with the 2019 version,including the selection and combination of urate-lowering drugs,anti-inflammatory and analgesic strategies for recurrent gout,urine alkalinization and dietary intervention,the diagnosis of gout with normal serum urate,flare risk assessment,and individualized management of patients with chronic kidney disease,heart failure/acute myocardial infarction,digestive diseases,type 2 diabetes mellitus,or osteoarthritis,in the hope of helping clinicians understand and apply the new guidelines accurately and improving long-term prognosis and quality of life of patients.
中国民族卫生协会重症代谢疾病分会 , 高尿酸血症相关疾病诊疗多学科共识专家组 . 中国高尿酸血症相关疾病诊疗多学科专家共识(2023年版) [J ] . 中国实用内科杂志 , 2023 , 43 ( 6 ): 461 - 480 .
China National Health Association Critical Care Metabolic Disease Branch , Multidisciplinary Expert Group on Diagnosis and Treatment of Hyperuricemia-Related Diseases . China multi-disciplinary expert consensus on diagnosis and treatment of hyperuricemia and related diseases(2023 edition) [J ] . Chin J Pract Intern Med , 2023 , 43 ( 6 ): 461 - 480 .
Liu S , Sun H , Yang S , et al . Clustering of gout-related comorbidities and their relationship with gout flares:a data-driven cluster analysis of eight comorbidities [J ] . J Endocrinol Invest , 2024 , 47 ( 5 ): 1119 - 1128 .
Howard RG , Samuels J , Gyftopoulos S , et al . Presence of gout is associated with increased prevalence and severity of knee osteoarthritis among older men:results of a pilot study [J ] . J Clin Rheumatol , 2015 , 21 ( 2 ): 63 - 71 .
Zhang M , Zhu XX , Wu J , et al . Prevalence of hyperuricemia among Chinese adults:findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19 [J ] . Front Immunol , 2021 , 12 : 791983 .
中华医学会内分泌学分会 . 中国高尿酸血症与痛风诊疗指南(2024)第一部分:对一般痛风患者的建议 [J ] . 中华内分泌代谢杂志 , 2025 , 41 ( 10 ): 806 - 816 .
Chinese Society of Endocrinology . Chinese guideline for the diagnosis and treatment of hyperuricemia and gout(2024) part 1:recommendations for general gout patients [J ] . Zhonghua Nei Fen Mi Dai Xie Za Zhi , 2025 , 41 ( 10 ): 806 - 816 .
中华医学会内分泌学分会 . 中国高尿酸血症与痛风诊疗指南(2024)第二部分:常见合并症患者的治疗建议 [J ] . 中华内分泌代谢杂志 , 2025 , 41 ( 11 ): 918 - 929 .
Chinese Society of Endocrinology . Chinese guideline for the diagnosis and treatment of hyperuricemia and gout(2024) part 2:recommendations for patients with common comorbidities [J ] . Zhonghua Nei Fen Mi Dai Xie Za Zhi , 2025 , 41 ( 11 ): 918 - 929 .
Xie H , Hu N , Pan T , et al . Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia:a meta-analysis of randomized controlled trials [J ] . BMC Pharmacol Toxicol , 2023 , 24 ( 1 ): 79 .
Liu XM , Wang HF , Ma RX , et al . The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5 [J ] . Clin Exp Nephrol , 2019 , 23 ( 3 ): 362 - 370 .
Mackenzie I S , Hawkey C J , Ford I , et al . Long-term safety and efficacy of febuxostat in patients with gout:the FAST trial [J ] . Lancet Rheumatol , 2020 , 2 ( 5 ): e254 - e262 .
Kohagura K , Satoh A , Kochi M , et al . Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension:a randomized trial [J ] . J Hypertens , 2023 , 41 ( 9 ): 1420 - 1428 .
Yan F , Xue XM , Lu J , et al . Superiority of low-dose benzbromarone to low-dose febuxostat in a prospective,randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion [J ] . Arthritis Rheumatol , 2022 , 74 ( 12 ): 2015 - 2023 .
Yu KH , Chen DY , Chen JH , et al . Management of gout and hyperuricemia:Multidisciplinary consensus in Taiwan,China [J ] . Int J Rheum Dis , 2018 , 21 ( 4 ): 772 - 787 .
Xue XM , Sun MS , Yan F , et al . Superiority of low-dose benzbromarone add-on to low-dose febuxostat compared with febuxostat monotherapy in gout with combined-type hyperuricemia [J ] . Arthritis Care Res , 2024 , 76 ( 5 ): 703 - 711 .
Vázquez-Mellado J , Cruz J , Guzmán S , et al . Severe tophaceous gout. Characterization of low socioeconomic level patients from México [J ] . Clin Exp Rheumatol , 2006 , 24 ( 3 ): 233 - 238 .
Huang ZP , Liu XQ , Liu YQ , et al . Clinical characteristics and risk factors of ulceration over tophi in patients with gout [J ] . Int J Rheum Dis , 2019 , 22 ( 6 ): 1052 - 1057 .
FitzGerald JD , Dalbeth N , Mikuls T , et al . 2020 American College of Rheumatology guideline for the management of gout [J ] . Arthritis Rheumatol , 2020 , 72 ( 6 ): 879 - 895 .
Xue Y , Chu TS , Hu JK , et al . Firsekibart in acute gouty arthritis [J ] . J Transl Med , 2025 , 23 ( 1 ): 91 .
Perez-Ruiz F . Treating to target:a strategy to cure gout [J ] . Rheumatology (Oxford) , 2009 , 48 ( Suppl 2 ):ii9-ii14.
Khanna D , Khanna PP , Fitzgerald JD , et al . 2012 American College of Rheumatology guidelines for management of gout. Part 2:therapy and antiinflammatory prophylaxis of acute gouty arthritis [J ] . Arthritis Care Res , 2012 , 64 ( 10 ): 1447 - 1461 .
Ughi N , Prevete I , Ramonda R , et al . The Italian Society of Rheumatology clinical practice guidelines for the diagnosis and management of gout [J ] . Reumatismo , 2019 , 71 ( S1 ): 50 - 79 .
Carvalho M , Erbano BO , Kuwaki EY , et al . Effect of potassium citrate supplement on stone recurrence before or after lithotripsy:systematic review and meta-analysis [J ] . Urolithiasis , 2017 , 45 ( 5 ): 449 - 455 .
Chi X , Cen YY , Yang BW , et al . Effects of dietary factors on hyperuricaemia and gout:a systematic review and meta-analysis of observational studies [J ] . Int J Food Sci Nutr , 2024 , 75 ( 8 ): 753 - 773 .
Zhu QR , Yu LL , Li YQ , et al . Association between dietary fiber intake and hyperuricemia among Chinese adults:analysis of the China adult chronic disease and nutrition surveillance (2015) [J ] . Nutrients , 2022 , 14 ( 7 ): 1433 .
Wang C , Sun WY , Dalbeth N , et al . Efficacy and safety of tart cherry supplementary citrate mixture on gout patients:a prospective,randomized,controlled study [J ] . Arthritis Res Ther , 2023 , 25 ( 1 ): 164 .
Martin KR , Coles KM . Consumption of 100% tart cherry juice reduces serum urate in overweight and obese adults [J ] . Curr Dev Nutr , 2019 , 3 ( 5 ): nzz011 .
Mao DH , Feng J , Zhou Y , et al . Analysis of different plant- and animal-based dietary patterns and their relationship with serum uric acid levels in Chinese adults [J ] . Nutr J , 2023 , 22 ( 1 ): 53 .
Simsek M , Opperman RCM , Mulder CJJ , et al . The teratogenicity of allopurinol:a comprehensive review of animal and human studies [J ] . Reprod Toxicol , 2018 , 81 : 180 - 187 .
Tong Q , Du Y , Cui R , et al . Risk of erectile dysfunction in male patients with gout treated with febuxostat or allopurinol:a propensity score-matched cohort study [J ] . Drugs , 2022 , 82 ( 18 ): 1717 - 1726 .
Li CH , Wang YY , Mu R , et al . Urate-lowering agents do not have clinically relevant negative effects on sperm quality and reproductive hormones in men with gout:a prospective open-label cohort study [J ] . Rheumatol Int , 2024 , 44 ( 7 ): 1245 - 1253 .
Sammaritano LR , Bermas BL , Chakravarty EE , et al . 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases [J ] . Arthritis Care Res , 2020 , 72 ( 4 ): 461 - 488 .
Lee JS , Kwon OC , Oh JS , et al . Clinical features and recurrent attack in gout patients according to serum urate levels during an acute attack [J ] . Korean J Intern Med , 2020 , 35 ( 1 ): 240 - 248 .
Shang J , Zhou LP , Wang H , et al . Diagnostic performance of dual-energy CT versus ultrasonography in gout:a meta-analysis [J ] . Acad Radiol , 2022 , 29 ( 1 ): 56 - 68 .
Neilson J , Bonnon A , Dickson A , et al . Gout:diagnosis and management-summary of NICE guidance [J ] . BMJ , 2022 , 378 : o1754 .
Cipolletta E , Abhishek A , Di Battista J , et al . Ultrasonography in the prediction of gout flares:a 12-month prospective observational study [J ] . Rheumatology (Oxford) , 2023 , 62 ( 3 ): 1108 - 1116 .
Stauder SK , Peloso PM . Dual-energy computed tomography has additional prognostic value over clinical measures in gout including tophi:a systematic literature review [J ] . J Rheumatol , 2022 , 49 ( 11 ): 1256 - 1268 .
Hu SH , Sun MS , Li MC , et al . Elevated serum CA72-4 predicts gout flares during urate lowering therapy initiation:a prospective cohort study [J ] . Rheumatology (Oxford) , 2023 , 62 ( 7 ): 2435 - 2443 .
Wang M , Li R , Qi H , et al . Metabolomics and machine learning identify metabolic differences and potential biomarkers for frequent versus infrequent gout flares [J ] . Arthritis Rheumatol , 2023 , 75 ( 12 ): 2252 - 2264 .
Loustau C , Rosine N , Forien M , et al . Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation:A multicentre,retrospective study [J ] . Joint Bone Spine , 2018 , 85 ( 6 ): 755 - 760 .
Wang YL , Dalbeth N , Terkeltaub R , et al . Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease [J ] . JAMA Intern Med , 2025 , 185 ( 1 ): 74 - 82 .
Sapankaew T , Thadanipon K , Ruenroengbun N , et al . Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia:systematic review and network meta-analysis of randomized controlled trials [J ] . BMC Nephrol , 2022 , 23 ( 1 ): 223 .
Tsukamoto S , Okami N , Yamada T , et al . Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients:a systematic review and network meta-analysis [J ] . Clin Rheumatol , 2022 , 41 ( 3 ): 911 - 919 .
Yood RA , Ottery FD , Irish W , et al . Effect of pegloticase on renal function in patients with chronic kidney disease:a post hoc subgroup analysis of 2 randomized,placebo-controlled,phase 3 clinical trials [J ] . BMC Res Notes , 2014 , 7 : 54 .
Bleyer A , Zhang Y , Kshirsagar O , et al . Pegloticase therapy in gout patients undergoing dialysis:a USRDS database study [J ] . Adv Chronic Kidney Dis , 2021 , 28 ( 1 ): 116 .
Ma ZJ , Chen J , Jin KQ , et al . Colchicine and coronary heart disease risks:a meta-analysis of randomized controlled clinical trials [J ] . Front Cardiovasc Med , 2022 , 9 : 947959 .
Tardif JC , Kouz S , Waters DD , et al . Efficacy and safety of low-dose colchicine after myocardial infarction [J ] . N Engl J Med , 2019 , 381 ( 26 ): 2497 - 2505 .
Saad Shaukat MH , Shabbir MA , Singh S , et al . Anakinra for colchicine-intolerant/colchicine-resistant acute gout flare precipitated by decompensated heart failure [J ] . Ir J Med Sci , 2021 , 190 ( 1 ): 129 - 131 .
McDowell K , Welsh P , Docherty KF , et al . Dapagliflozin reduces uric acid concentration,an independent predictor of adverse outcomes in DAPA-HF [J ] . Eur J Heart Fail , 2022 , 24 ( 6 ): 1066 - 1076 .
Doehner W , Anker SD , Butler J , et al . Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction:the EMPEROR-reduced trial [J ] . Eur Heart J , 2022 , 43 ( 36 ): 3435 - 3446 .
Myhre PL , Vaduganathan M , O’Meara E , et al . Mechanistic effects of spironolactone on cardiovascular and renal biomarkers in heart failure with preserved ejection fraction:a TOPCAT biorepository study [J ] . Circ Heart Fail , 2020 , 13 ( 1 ): e006638 .
Wechalekar MD , Vinik O , Moi JH , et al . The efficacy and safety of treatments for acute gout:results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids,colchicine,nonsteroidal antiinflammatory drugs,and interleukin-1 inhibitors [J ] . J Rheumatol Suppl , 2014 , 92 : 15 - 25 .
Thueringer JT , Doll NK , Gertner E . Anakinra for the treatment of acute severe gout in critically ill patients [J ] . Semin Arthritis Rheum , 2015 , 45 ( 1 ): 81 - 85 .
中华医学会内分泌学分会 . 中国高尿酸血症与痛风诊疗指南(2019) [J ] . 中华内分泌代谢杂志 , 2020 , 36 ( 1 ): 1 - 13 .
Chinese Society of Endocrinology . Chinese guideline for the diagnosis and treatment of hyperuricemia and gout (2019) [J ] . Zhonghua Nei Fen Mi Dai Xie Za Zhi , 2020 , 36 ( 1 ): 1 - 13 .
da Costa BR , Pereira TV , Saadat P , et al . Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis:network meta-analysis [J ] . BMJ , 2021 , 375 : n2321 .
Salis Z , Sainsbury A . Association of long-term use of non-steroidal anti-inflammatory drugs with knee osteoarthritis:a prospective multi-cohort study over 4-to-5 years [J ] . Sci Rep , 2024 , 14 : 6593 .
Bruyère O , Honvo G , Veronese N , et al . An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis,Osteoarthritis and Musculoskeletal Diseases(ESCEO) [J ] . Semin Arthritis Rheum , 2019 , 49 ( 3 ): 337 - 350 .
Nielsen SM , Bartels EM , Henriksen M , et al . Weight loss for overweight and obese individuals with gout:a systematic review of longitudinal studies [J ] . Ann Rheum Dis , 2017 , 76 ( 11 ): 1870 - 1882 .
Holden MA , Hattle M , Runhaar J , et al . Moderators of the effect of therapeutic exercise for knee and hip osteoarthritis:a systematic review and individual participant data meta-analysis [J ] . Lancet Rheumatol , 2023 , 5 ( 7 ): e386 - e400 .
Xiao L , Lin SD , Zhan F . The association between serum uric acid level and changes of MRI findings in knee osteoarthritis:a retrospective study(a STROBE-compliant article) [J ] . Medicine , 2019 , 98 ( 21 ): e15819 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621